Clontech Licenses CRISPR/CAS9 Technology From Broad Institute
News Oct 28, 2014
"Clontech is pleased to be able to provide innovative tools for CRISPR/Cas9 gene editing under our Guide-it™ brand," commented Carol Lou, General Manager of Clontech Laboratories, Inc. "We believe that CRISPR/Cas9 technology represents a significant improvement over existing genome editing tools, reaching a new level of targeting, efficiency, and in particular ease of use. It is destined to become as valuable and widely utilized as RNAi; perhaps more so."
Clontech's initial product offering includes Guide-it kits for in vitro production and screening of single guide RNAs (sgRNAs) and a method to confirm the presence of targeted mutations using direct PCR and Clontech's Guide-it Resolvase enzyme.
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.